Phase II trial of pembrolizumab for patients suffering from metastatic castration resistant prostate cancer (mCRPC) with DNA repair defects, high tumour mutation burden, and/or high CD3 counts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback